Free Trial

PTC Therapeutics (PTCT) Competitors

PTC Therapeutics logo
$48.57 +0.92 (+1.93%)
As of 01:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PTCT vs. ITCI, GMAB, RDY, QGEN, MRNA, ASND, VTRS, BPMC, BBIO, and VRNA

Should you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry.

PTC Therapeutics vs. Its Competitors

PTC Therapeutics (NASDAQ:PTCT) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

In the previous week, PTC Therapeutics had 7 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 8 mentions for PTC Therapeutics and 1 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 0.00 beat PTC Therapeutics' score of -0.33 indicating that Intra-Cellular Therapies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PTC Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Intra-Cellular Therapies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

PTC Therapeutics has a net margin of 33.56% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat PTC Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
PTC Therapeutics33.56% -78.56% 32.11%
Intra-Cellular Therapies -14.07%-9.93%-8.38%

92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Intra-Cellular Therapies has lower revenue, but higher earnings than PTC Therapeutics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PTC Therapeutics$1.77B2.19-$363.30M$6.517.51
Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64

PTC Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.

PTC Therapeutics presently has a consensus price target of $65.00, suggesting a potential upside of 32.99%. Intra-Cellular Therapies has a consensus price target of $109.70, suggesting a potential downside of 16.81%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe PTC Therapeutics is more favorable than Intra-Cellular Therapies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PTC Therapeutics
1 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.67
Intra-Cellular Therapies
0 Sell rating(s)
10 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

Summary

PTC Therapeutics beats Intra-Cellular Therapies on 11 of the 17 factors compared between the two stocks.

Get PTC Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PTCT vs. The Competition

MetricPTC TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.87B$2.91B$5.53B$8.98B
Dividend YieldN/A2.45%5.25%4.04%
P/E Ratio7.5120.8927.0720.16
Price / Sales2.19289.54430.62124.91
Price / CashN/A41.1936.8257.86
Price / Book-3.437.728.075.57
Net Income-$363.30M-$54.95M$3.17B$248.52M
7 Day Performance-0.56%5.01%3.91%5.05%
1 Month Performance-5.44%4.38%3.63%6.98%
1 Year Performance54.92%6.59%34.00%21.36%

PTC Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PTCT
PTC Therapeutics
4.2854 of 5 stars
$48.57
+1.9%
$65.00
+33.8%
+50.2%$3.85B$1.77B7.461,410
ITCI
Intra-Cellular Therapies
0.7433 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560News Coverage
GMAB
Genmab A/S
4.0127 of 5 stars
$20.66
+0.8%
$37.60
+82.0%
-16.6%$13.25B$3.12B11.742,682News Coverage
Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.7102 of 5 stars
$15.03
-0.3%
$16.95
+12.8%
-4.7%$12.55B$3.81B22.7727,811
QGEN
Qiagen
3.8919 of 5 stars
$48.07
+0.6%
$49.40
+2.8%
+22.3%$10.69B$1.98B120.525,765
MRNA
Moderna
4.4623 of 5 stars
$27.59
+1.6%
$46.61
+68.9%
-72.1%$10.67B$3.24B-3.165,800
ASND
Ascendis Pharma A/S
2.7027 of 5 stars
$172.60
+0.2%
$220.67
+27.8%
+23.2%$10.55B$393.54M-27.481,017
VTRS
Viatris
2.6649 of 5 stars
$8.93
-0.9%
$10.40
+16.5%
-12.7%$10.48B$14.74B-2.8232,000
BPMC
Blueprint Medicines
1.5096 of 5 stars
$128.18
+0.1%
$128.06
-0.1%
+10.4%$8.28B$562.12M-51.89640News Coverage
Insider Trade
BBIO
BridgeBio Pharma
4.677 of 5 stars
$43.18
-3.7%
$58.85
+36.3%
+65.2%$8.20B$221.90M-12.23400Analyst Upgrade
Gap Up
High Trading Volume
VRNA
Verona Pharma PLC American Depositary Share
1.8842 of 5 stars
$94.58
+0.8%
$101.10
+6.9%
+410.6%$8.05B$42.28M-47.2930News Coverage
Positive News
Gap Up

Related Companies and Tools


This page (NASDAQ:PTCT) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners